Brief: Sensorion Provides Update On Notoxis

Sensorion SA

18/12/2023 06:32

Dec 18 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION PROVIDES AN UPDATE ON NOTOXIS, ITS PROOF OF
CONCEPT
PHASE 2A CLINICAL TRIAL OF SENS-401 IN CISPLATIN-INDUCED
OTOTOXICITY (CIO)
    * RECRUITMENT IS PROGRESSING WELL, WITH OVER A THIRD OF
REQUIRED
STUDY POPULATION ENROLLED
    * POC PHASE 2A CLINICAL TRIAL OF SENS-401 IN PREVENTION OF
RESIDUAL HEARING LOSS AFTER COCHLEAR IMPLANTATION IS ADVANCING
AS PLANNED. END OF PATIENT RECRUITMENT IS ANTICIPATED EARLY 2024
    * SENSORION WILL PROVIDE FURTHER UPDATES OF ITS PROOF OF
CONCEPT
(POC) PHASE 2A CLINICAL TRIAL OF SENS-401 CIO DURING WORLD
CONGRESS OF AUDIOLOGY, BEING HELD ON SEPTEMBER 19-22, 2024, IN
PARIS, FRANCE

Source text for Eikon:  ID:nBw3FxKB1a 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))